Stockholm - Delayed Quote SEK
Cantargia AB (publ) (CANTA.ST)
At close: November 6 at 5:29 PM GMT+1
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
233,070.0000
287,765.0000
379,650.0000
368,018.0000
173,315.0000
Operating Income
-233,070.0000
-287,765.0000
-379,650.0000
-368,018.0000
-173,315.0000
Net Non Operating Interest Income Expense
1,637.0000
4,264.0000
384.0000
924.0000
500.0000
Pretax Income
-227,959.0000
-280,027.0000
-371,814.0000
-366,504.0000
-173,085.0000
Net Income Common Stockholders
-227,959.0000
-280,027.0000
-371,814.0000
-366,504.0000
-173,085.0000
Diluted NI Available to Com Stockholders
-227,959.0000
-280,027.0000
-371,814.0000
-366,504.0000
-173,085.0000
Basic EPS
-1.30
-1.65
-2.90
-3.66
-1.61
Diluted EPS
-1.30
-1.65
-2.90
-3.66
-1.61
Basic Average Shares
178,120.3940
169,771.0000
128,024.0000
100,193.0000
107,402.3060
Diluted Average Shares
178,120.3940
169,771.0000
128,024.0000
100,193.0000
107,402.3060
Total Operating Income as Reported
-235,322.0000
-290,017.0000
-381,549.0000
-370,267.0000
-173,945.0000
Rent Expense Supplemental
--
--
--
--
1,135.0000
Total Expenses
233,070.0000
287,765.0000
379,650.0000
368,018.0000
173,315.0000
Net Income from Continuing & Discontinued Operation
-227,959.0000
-280,027.0000
-371,814.0000
-366,504.0000
-173,085.0000
Normalized Income
-233,623.0000
-285,691.0000
-371,814.0000
-366,504.0000
-173,085.0000
Interest Income
1,637.0000
4,265.0000
388.0000
927.0000
501.0000
Interest Expense
--
1.0000
4.0000
3.0000
1.0000
Net Interest Income
1,637.0000
4,264.0000
384.0000
924.0000
500.0000
EBIT
-227,959.0000
-280,026.0000
-371,810.0000
-366,501.0000
-173,084.0000
EBITDA
-224,512.0000
-276,576.0000
-368,118.0000
-363,055.0000
-169,836.0000
Reconciled Depreciation
3,447.0000
3,450.0000
3,692.0000
3,446.0000
3,248.0000
Net Income from Continuing Operation Net Minority Interest
-227,959.0000
-280,027.0000
-371,814.0000
-366,504.0000
-173,085.0000
Total Unusual Items Excluding Goodwill
5,664.0000
5,664.0000
--
--
--
Total Unusual Items
5,664.0000
5,664.0000
--
--
--
Normalized EBITDA
-230,176.0000
-282,240.0000
-368,118.0000
-363,055.0000
-169,836.0000
12/31/2020 - 3/17/2015
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
HNSA.ST Hansa Biopharma AB (publ)
32.32
-3.69%
ONCO.ST Oncopeptides AB (publ)
2.0750
-0.24%
MVIR.ST Medivir AB (publ)
2.8900
+0.35%
XBRANE.ST Xbrane Biopharma AB (publ)
0.2075
-6.74%
ATORX.ST Alligator Bioscience AB (publ)
0.6620
-8.06%
ISOFOL.ST Isofol Medical AB (publ)
3.3300
-4.86%
XSPRAY.ST Xspray Pharma AB (publ)
48.45
-14.25%
EGTX.ST Egetis Therapeutics AB (publ)
4.1000
-0.97%
SANION.ST Saniona AB (publ)
3.1950
-38.32%
ABLI.ST Abliva AB (publ)
0.1530
+2.27%